Lanthier vs NbN3

“Lanthier” is an internal medicine app based on the seventh edition of the bestselling pocketbook. Completely re-imagined for iOS, this app will allow any physician, resident or medical student to access up-to-date medical information and guidelines quickly and efficiently. Free 7 days trial subscription! “Lanthier Practical Guide to Internal Medicine is a good choice for an app to replace your pocketbook. Beyond providing quality content with references, it has an excellent design that makes it more than just a digitized version of a book. Finding clinically relevant information about a condition is quick and easy.” iMedicalApp.com — FEATURES — • Concise: edited to be useful at the bedside. • Fast: advanced search function, intuitive menus. • Direct link to the references on PubMed and now through Read by QxMD (internet connection required). Build your paper collection using articles selected by Dr Lanthier himself. • MedCalX integration (sold separately): for quick access to the trusted medical calculator. • Take personal notes within the topics and synchronize them across your iOS devices. Perfect for studying for board exams! — TOPICS — Cardiology Dermatology (new) Endocrinology Gastroenterology General Internal Medicine Hematology Infectious Diseases Nephrology Neurology Oncology Pneumology Rheumatology — ABOUT THE LEAD AUTHORS — Dr Luc Lanthier practices General Internal Medicine at the Sherbrooke University Hospital Center and is a Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Sherbrooke. He is former chair of the French Examination Board for Internal Medicine Exam at the Royal College of Physicians and Surgeons of Canada. Dr Donald Echenberg practices General Internal Medicine at the Sherbrooke University Hospital Center and is an Associate Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Sherbrooke. He is past president of the Canadian Society of Internal Medicine and is currently Governor of the Quebec Chapter of the American College of Physicians. — DISCLAIMER — This publication (application) is to be used as a guide only. It is intended only for use by licensed medical practitioners and medical students. Every doctor (or prescriber) is responsible for their actions. Therapeutic options presented in this guide reflect current approaches and guidelines in the field of internal medicine. Content has been peer reviewed by leading experts in their respective fields. The authors of Lanthier - Practical Guide to Internal Medicine shall not be liable for any injury and/or damage to persons or property arising from the use of this application. This guide is not meant to replace clinical judgment. It is the responsibility of the licensed prescriber to verify the indications, contraindications and dosage of the medication (and actions) they prescribe. — ABOUT SUBSCRIPTION — Lanthier - Internal Medicine is offered as a subscription service, renewed automatically. Payment will be charged to iTunes Account at confirmation of purchase. The subscription will automatically renew unless auto-renew is turned off at least 24-hours before the end of the current period. The iTunes Account will be charged for renewal within 24-hours prior to the end of the current period. Subscriptions may be managed by the user and auto-renewal may be turned off by going to the application «Settings» section and tapping «Manage Subscriptions» after purchase. For more information on Terms of Use visit https://lanthiermed.com/terms-of-use

It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients. This practice is confusing. • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature. • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”. • In this second edition 22 new medications were added so NbN includes now 130 medications. This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth. The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.   Therefore this nomenclature is based on: 1. The need to treat now. 2. Updated neuroscience insights. 3. The judgment of the members of the taskforce. Along these lines, we have come up with the following proposal: The Nomenclature: Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action. We also added 4 additional dimensions 4 Additional Dimensions: Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included  Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve" Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.   As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.